Summary
Second-line intraperitoneal (i.p.) therapy has been demonstrated to result in surgically defined complete responses (S-CR) in 25%–40% of patients with small-volume residual ovarian cancer (microscopic disease or largest tumor mass <1 cm in diameter). To evaluate the influence of the surgical finding of diffuse peritoneal carcinomatosis on the S-CR rate to salvage i.p. therapy in this patient population, we retrospectively reviewed the operative reports of 70 patients with small-volume residual ovarian cancer treated on one of three phase-2 second-line i.p. trials at the Memorial Sloan-Kettering Cancer Center. Of the 11 patients with diffuse carcinomatosis, none achieved a S-CR compared to a S-CR rate of 37% (22/59) in patients without this surgical finding (χ2=6.0;P<0.025). However, of the 7 patients with diffuse carcinomatosis treated on a cisplatin-based i.p. program, the only 2 who had previously responded to systemic platinum also experienced a response (partial) to the i.p. cisplatin regimen. In conclusion, while the surgical finding of diffuse peritoneal carcinomatosis indicates a poor prognosis in patients with small-volume residual ovarian cancer for response to i.p. chemotherapy, patients in this clinical setting with prior evidence of platinum sensitivity may experience some benefit from an i.p. cisplatin-based treatment strategy.
Similar content being viewed by others
References
Alberts DS, Young L, Mason N, Salmon SE (1985) In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12 [Suppl 4]:38–42
Andrews PA, Velury S, Mann SC, Howell SB (1988)cis-Diaminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48:68–73
Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–9
Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVie JG (1989) Direct diffusion ofcis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380–3384
Markman M (1986) Intraperitoneal anti-neoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 13:219–242
Markman M (1991) Intraperitoneal chemotherapy. Semin Oncol 18:248–254
Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1990) Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 8:146–150
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Yordan EL Jr, Eriksson J, Lewis JL Jr (1991a) Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol 9:204–210
Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W (1991b) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to systemic cisplatin. J Clin Oncol 9:1801–1805
Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC (1979) Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214
Ozols RF, Corden BJ, Jacob, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19–24
Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, Almadrones L, Ochoa M Jr, Chapman D, Saigo P, Lewis JL Jr (1989) Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol 7:1327–1332
Author information
Authors and Affiliations
Additional information
Supported in part by the Avon Program in Ovarian Cancer, Memorial Sloan-Kettering Cancer Center
Rights and permissions
About this article
Cite this article
Markman, M., Reichman, B., Hakes, T. et al. Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate. J Cancer Res Clin Oncol 118, 235–237 (1992). https://doi.org/10.1007/BF01410140
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01410140